Fig. 6

The effect of miR-129 and miR-125b in KGN cells with silencing lncRNA SNHG12. a, b FCM was used for testing the apoptosis in KGN cells in each group and the analysis of cell apoptosis, si- SNHG12: si-RNA-lncRNA SNHG12, n = 3 in each group; c CCK-8 assays were used to test cell viability at 24, 48, 72, and 96 h in KGN cells in each group, n = 5 in each group; d The levels of miR-129 and miR-125b in KGN cells with miR-129 and miR-125b inhibitor treatment were measured by qRT-PCR, n = 3 in each group; ^#P < 0.05, ^##P < 0.01 vs. insulin + siRNA-NC group; ^&P < 0.05, ^&&P < 0.01 vs. insulin + siRNA-lncRNA SNHG12 group; e The relative luciferase ratio in KGN cells co-transfected with SNHG12 WT luciferase vector and miR-129, miR-125b mimics, n = 3 in each group, ^#P < 0.05, ^##P < 0.01 vs. insulin + siRNA-NC group; f Anti-Ago2 RNA Binding Protein Immunoprecipitation (RIP) assay was used to pull down endogenous RNAs associated with Ago2; IgG served as the control. The levels of miR-129 and miR-125b were measured by qRT-PCR. n = 5 in each group, ^•P < 0.05, ^••P < 0.01 vs. the input group